Efficacy and safety of Anluohuaxian in the treatment of patients with severe Coronavirus disease 2019- a multicenter, open label, randomized controlled study: a structured summary of a study protocol for a randomised controlled trial

Efficacy and safety of Anluohuaxian in the treatment of patients with severe Coronavirus disease 2019- a multicenter, open label, randomized controlled study: a structured summary of a study protocol for a randomised controlled trial

Abstract Objectives Patients with severe COVID-19 often suffer from significant pulmonary fibrosis. Although the pathogenesis of pulmonary fibrosis has not been fully explained, the signal pathways and cytokines involved are very similar to hepatic fibrosis. This has been successfully treated with t...

Full description

Bibliographic Details
Main Authors: Chi Zhang, Jiawen Li, Zhao Wu, He Wang, Chengli Que, Hong Zhao, Guiqiang Wang
Format: Article
Language:English
Published: BMC 2020-06-01
Series:Trials
Subjects:
COVID-19
Randomised controlled trial
Protocol
Pulmonary fibrosis
Anluohuaxian
Online Access:http://link.springer.com/article/10.1186/s13063-020-04399-8

Internet

http://link.springer.com/article/10.1186/s13063-020-04399-8

Similar Items